Hologic (NASDAQ:HOLX) 株価情報

Hologic

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Hologic Inc

<p><strong>Hologic's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NYSE">HOLX</a>) short percent of float has risen 11.34% since its last report. The company recently reported that it has <strong>6.53 million shares sold short</strong>, which is 3.83% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.33 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Hologic Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1744999217_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Hologic has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Hologic's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Hologic's peer group average for short interest as a percentage of float is 4.37%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

HOLX

How Is The Market Feeling About Hologic?

<p><strong>Hologic's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NYSE">HOLX</a>) short percent of float has fallen 25.07% since its last report. The company recently reported that it has <strong>4.44 million shares sold short</strong>, which is 2.6% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.44 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Hologic Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741808832_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Hologic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Hologic's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Hologic's peer group average for short interest as a percentage of float is 4.17%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


How Do Investors Really Feel About Hologic?

<p>Across the recent three months, 11 analysts have shared their insights on Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Hologic, revealing an average target of $83.09, a high estimate of $90.00, and a low estimate of $70.00. Highlighting a 3.05% decrease, the current average has fallen from the previous average price target of $85.70. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741118472_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Hologic among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$73.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$82.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$85.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hologic compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Hologic's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Hologic analyst ratings.</strong></a></p>
<h2>Delving into Hologic's Background</h2>
<p>Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.</p>
<h3>Hologic: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Hologic's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.86%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Hologic's net margin excels beyond industry benchmarks, reaching <strong>19.67%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Hologic's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.06%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Hologic's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.25%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.53</strong>, Hologic adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

11 Analysts Have This To Say About Hologic

<p>Citigroup  analyst Patrick Donnelly   maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Neutral and lowers the price target from $80 to $70.</p>


News

Price Target

Citigroup Maintains Neutral on Hologic, Lowers Price Target to $70

Hologic Granted FDA Clearance For Aptima SARS-CoV-2 Assay

<p>Raymond James  analyst Andrew Cooper   reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and lowers the price target from $95 to $90.</p>


Reiteration

Raymond James Reiterates Outperform on Hologic, Lowers Price Target to $90

<p>RBC Capital  analyst Conor McNamara   maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Sector Perform and lowers the price target from $88 to $85.</p>


RBC Capital Maintains Sector Perform on Hologic, Lowers Price Target to $85

<p>Evercore ISI Group  analyst Vijay Kumar   maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a In-Line and lowers the price target from $76 to $73.</p>


Evercore ISI Group Maintains In-Line on Hologic, Lowers Price Target to $73

<p>Stephens &amp; Co.  analyst Mason Carrico   reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Overweight and maintains $84 price target.</p>


Stephens & Co. Reiterates Overweight on Hologic, Maintains $84 Price Target

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Evercore ISI Group raised <strong>Arm Holdings plc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) price target from $176 to $202. Evercore ISI Group analyst Mark Lipacis maintained an Outperform rating. Arm shares closed at $173.26 on Wednesday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for <strong>Amgen Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) from $256 to $275. B of A Securities analyst Tim Anderson maintained an Underperform rating. Amgen shares closed at $307.81 on Wednesday. <a href="https://www.benzinga.com/quote/AMGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital boosted <strong>Fiserv, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) price target from $233 to $260. BMO Capital analyst Rufus Hone maintained an Outperform rating. Fiserv shares closed at $229.53 on Wednesday. <a href="https://www.benzinga.com/quote/FI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised the price target for <strong>Coherent Corp</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) from $105 to $115. Rosenblatt analyst Mike Genovese maintained a Neutral rating. Coherent shares closed at $90.10 on Wednesday. <a href="https://www.benzinga.com/quote/COHR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Northland Capital Markets cut the price target for <strong>CSG Systems International, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGS#NASDAQ">CSGS</a>) from $78 to $80. Northland Capital Markets analyst Nehal Chokshi reiterated an Outperform rating. CSG Systems shares closed at $61.66 on Wednesday. S<a href="https://www.benzinga.com/quote/CSGS/analyst-ratings">ee how other analysts view this stoc</a>k.</li>
<li>Piper Sandler slashed <strong>Skyworks Solutions, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) price target from $85 to $70. Piper Sandler analyst Harsh Kumar maintained a Neutral rating. Skyworks shares settled at $87.08 on Wednesday. <a href="https://www.benzinga.com/quote/SWKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut <strong>PepsiCo, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) price target from $158 to $153. Barclays analyst Lauren Lieberman maintained an Overweight rating. PepsiCo shares closed at $145.66 on Wednesday. <a href="https://www.benzinga.com/quote/PEP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut <strong>Hologic, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) price target from $80 to $75. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. Hologic shares closed at $72.80 on Wednesday.  <a href="https://www.benzinga.com/quote/HOLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised the price target for <strong>Workday, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from $300 to $310. Goldman Sachs analyst Kash Rangan maintained a Buy rating. Workday shares settled at $276.17 on Wednesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed <strong>Uber Technologies, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) price target from $82 to $80. Piper Sandler analyst Thomas Champion maintained an Overweight rating. Uber shares closed at $64.48 on Wednesday. <a href="https://www.benzinga.com/quote/UBER/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></strong></li>
</ul>


Pre-Market Outlook

Markets

AMGN

COHR

CSGS

SWKS

UBER

WDAY

Uber To $80? Here Are 10 Top Analyst Forecasts For Thursday

<p>U.S. stock futures were higher this morning, with the Dow Jones futures gaining around 100 points on Thursday.</p>
<p>Shares of <strong>Ford Motor Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) fell sharply in today's pre-market trading after the company said that it expects $5 billion to $5.5 billion in losses in its EV segment this year, in line with the loss <a href="https://www.benzinga.com/tech/25/02/43522408/ford-slides-5-pre-market-after-disappointing-outlook-high-loss-from-ev-segment-in-2024">recorded last year</a>.</p>
<p>Ford said it sees full-year 2025 adjusted EBIT in a range of $7 billion to $8.5 billion, adjusted free cash flow in a range of $3.5 billion to $4.5 billion, and capital spending in a range of $8 billion to $9 billion.</p>
<p>Meanwhile, Ford reported upbeat fourth-quarter financial results on Wednesday.</p>
<p>Ford Motor shares dipped 6.1% to $9.40 in the pre-market trading session.</p>
<p>Here are some other stocks moving lower in pre-market trading.</p>
<ul>
<li><strong>Skyworks Solutions, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) dipped 29.2% to $61.65 in pre-market trading after the company issued second-quarter adjusted EPS guidance below estimates..</li>
<li><strong>FormFactor, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) fell 27.7% to $29.78 in today's pre-market trading after the company reported worse-than-expected fourth-quarter adjusted EPS results and issued cirst-quarter guidance below estimates.</li>
<li><strong>Matrix Service Company</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTRX#NASDAQ">MTRX</a>) shares fell 26.1% to $10.38 in pre-market trading after the company reported second-quarter financial results and cut its FY25 sales guidance below estimates.</li>
<li><strong>SunCar Technology Group Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) fell 18.3% to $6.90 in pre-market trading after the company reported the pricing of $50 million follow-on public offering of class a ordinary shares.   </li>
<li><strong>Symbotic Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) fell 16.6% to $25.80 in pre-market trading. Symbotic reported quarterly losses of three cents per share which missed the analyst consensus estimate for losses of two cents. Quarterly revenue of $486.69 million also missed the analyst consensus estimate of $490.98 million.</li>
<li><strong>Mach Natural Resources LP</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) declined 6.9% to $16.00 in pre-market trading as the company announced the launch of 12 million common unit offering.</li>
<li><strong>Mineralys Therapeutics, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) fell 5.5% to $9.70 in pre-market trading. Mineralys Therapeutics will report its financial results from the fourth quarter, before the opening bell on Wednesday, Feb. 12.</li>
<li><strong>Hologic, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) slipped 4.9% to $69.22 in pre-market trading following quarterly results.</li>
<li><strong>QUALCOMM Incorporated</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) fell 4.7% to $167.50 in pre-market trading following first-quarter results.</li>
<li><strong>Arm Holdings plc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) fell 4.2% to $166.06 in pre-market trading. Arm Holdings reported better-than-expected third-quarter financial results for fiscal year 2025 after the market closed on Wednesday. Arm said it expects fourth-quarter revenue of $1.175 billion to $1.275 billion. The company anticipates fourth-quarter adjusted earnings of 48 cents to 56 cents per share. The company also narrowed its full-year guidance.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></strong></li>
</ul>


Movers

FORM

MLYS

MTRX

QCOM

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

Ford, Skyworks Solutions, FormFactor And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

<p>Leerink Partners  analyst Puneet Souda   downgrades Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Outperform to Market Perform and lowers the price target from $80 to $75.</p>


Downgrades

Leerink Partners Downgrades Hologic to Market Perform, Lowers Price Target to $75

WIIM

Hologic shares are trading lower after the company cut its FY25 revenue outlook.

<p>Needham  analyst Mike Matson   reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Hold to Hold.</p>


Needham Reiterates Hold on Hologicto Hold

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) reported its Q1 earnings results on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Hologic Q1 Earnings Assessment

<p>The Q1 earnings report for <strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) was released on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>The company missed on EPS by $0.0 in the last quarter, resulting in a 6.0% drop share price change the following day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Hologic Q1

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) just disclosed its Q1 earnings on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hologic Q1 Earnings Summary & Key Takeaways

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) announced its Q1 earnings on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hologic Earnings Report: Q1 Overview

Guidance

Hologic Expects Q2 Revenue Of $995M - $1.005B (Est $1.036B), Adj EPS Of $1.00 - $1.03 ((Est $1.03)

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) just disclosed its Q1 earnings on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 6.0% drop in the share price the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

Hologic

ニュース

パートナーシップ

ベンジンガ・グローバル